Caribou Biosciences, Inc. (CRBU) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Berkeley, CA, United States. Der aktuelle CEO ist Rachel E. Haurwitz.
CRBU hat IPO-Datum 2021-07-23, 147 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $212.6M.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
